Dantrolene in the treatment of MDMA-related hyperpyrexia: A systematic review

Canadian Journal of Emergency Medicine

Volumn 12, Issue 5, 2010, Pages 435-442

  Grunau, Brian E ^a   Wiens, Matthew O ^a,b   Brubacher, Jeffrey R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Chilliwack General Hospital   (Canada)

Author keywords

Dantrolene; MDMA; MDMA related hyperpyrexia; Toxicology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DANTROLENE; CENTRAL MUSCLE RELAXANT;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AGE DISTRIBUTION; AGITATION; BLEEDING; BLOOD CLOTTING DISORDER; BODY TEMPERATURE; BRAIN EDEMA; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; COMPARTMENT SYNDROME; COOLING; DEATH; DELIRIUM; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPYREXIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPONATREMIA; LIVER TOXICITY; LUNG EDEMA; MEDLINE; METABOLIC ACIDOSIS; NEUROLOGIC DISEASE; PANCREAS NECROSIS; PARALYSIS; REVIEW; RHABDOMYOLYSIS; SCORING SYSTEM; SEIZURE; SHOCK; SURVIVAL; SURVIVAL RATE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); FEVER;

CLINICAL TRIALS AS TOPIC; DANTROLENE; FEVER; HUMANS; MUSCLE RELAXANTS, CENTRAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SURVIVAL ANALYSIS;

EID: 79952197850     PISSN: 14818035     EISSN: 14818035     Source Type: Journal    
DOI: 10.1017/S1481803500012598     Document Type: Review

References (83)

1. Merck E, inventor. Varfeharen Zur Darstellung Von Alkyloxyaryl- Dialyoxyaryl-Und Alkylenedioxyarylaminopropanen Bzw. Deren Am Stickstoff Monoalkylierten. German patent 274350. 1914.
2. Adlaf EM, Begin P, Sawka E. Canadian Addiction Survey (CAS): a national survey of Canadians' me of alcohol and other drugs: prevalence of use and related harms, detailed report. Ottawa (ON): Canadian Centre on Substance Abuse; 2005.
3. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2007. MMWR Surveill Summ 2008;57:1-131.
4. Gore SM. Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet 1999;354:1265-6 (Pubitemid 29469362)
5. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
6. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 2001;165:917-28.
7. Iravani MM, Asari D, Patel J, et al. Direct effects of 3, 4-methylenedioxymethamphetamine (MDMA) on serotonin or dopamine release and uptake in the caudate putamen, nucleus accumbens, substantia nigra pars reticulata, and the dorsal raphe nucleus slices. Synapse 2000;36:275-85. (Pubitemid 30257312)
8. Hall AP, Henry JA. Acute toxic effects of "ecstacy" (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006;96:678-85.
9. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
10. Larner AJ. Dantrolene and "ecstasy" overdose. Anaesthesia 1993;48:179-80.
11. Stone RJ. Treatment of "ecstasy" overdose with dantrolene. Anaesthesia 1993;48:83.
12. Wappler F, Fiege M, Schulte am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 2001;87:794-8. (Pubitemid 33069576)
13. Fiege M, Wappler F, Weisshorn R, et al. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy"). Anesthesiology 2003;99: 1132-6. (Pubitemid 37339459)
14. Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia 1992;47:686-7.
15. Logan AS, Stickle B, O'Keefe N, et al. Survival following "ecstasy" ingestion with a peak temperature of 42 degrees C. Anaesthesia 1993;48:1017-8.
16. Moon J, Cros J. Role of dantrolene in the management of the acute toxic effects of ecstasy (MDMA). Br J Anaesth 2007; 99:146. (Pubitemid 47072575)
17. Vale A. Amfetamines including MDMA (ecstasy). Medicine 2007;35:582. (Pubitemid 47610349)
18. Mallick A, Bodenham AR. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 1997;14:336-8.
19. Webb C, Williams V. Ecstasy intoxication: appreciation of complications and the role of dantrolene. Anaesthesia 1993; 48:542-3. (Pubitemid 23193292)
20. Tehan B. Ecstasy and dantrolene. BMJ 1993;306:146.
21. Bodenham AR, Mallick A. New dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives. Intensive Care Med 1996;22:622-4. (Pubitemid 26254268)
22. Duffy MR, Ferguson C. Role of dantrolene in treatment of heat stroke associated with ecstasy ingestion. Br J Anaesth 2007;98:148-9. (Pubitemid 44896771)
23. Watson JD, Ferguson C, Hinds CJ, et al. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993;48:1057-60.
24. Barrett PJ. Ecstasy and dantrolene. BMJ 1992;305:1225.
25. Hallucinogenic amphetamines. In: Poison management manual. 4th ed. Vancouver (BC): BC Drug and Poison Information Centre; 1997. p. 70.
26. Toxbase. Monograph MDMA. Available: www.toxbase.co.uk (accessed 2009 Mar. 25)
27. Rusyniak DE, Banks ML, Mills EM, et al. Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Anesthesiology 2004;101:263, author reply 264.
28. Denborough MA, Hopkinson KC. Dantrolene and "ecstasy." Med J Aust 1997;166:165-6.
29. Hall AP. Dantrolene and "ecstasy." Med J Aust 1997;167: 506-7.
30. Strobbe L, de Jaer CP, Louwerse ES, et al. [Fatal ecstasy intoxication in a 22-year-old man] [article in Dutch]. Ned Tijdschr Geneeskd 2007;151:2295.
31. Tehan B, Hardern R, Bodenham A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ("Eve"). Anaesthesia 1993;48:507-10.
32. Bouchama A, Cafege A, Devol EB, et al. Ineffectiveness of dantrolene sodium in the treatment of heatstroke. Crit Care Med 1991;19:176-80.
33. Dar KJ, McBrien ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med 1996;22:995-6. (Pubitemid 26340654)
34. Gordon CJ, Watkinson WP, O'Callaghan JP, et al. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991;38:339-44.
35. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Psychopharmacology (Berl) 1995;119:247-60.
36. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of "ecstasy" (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995;115:1281-9.
37. Patel MM, Belson MG, Longwater AB, et al. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 2005;29:451-4.
38. de la Torre R, Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004;25:505-8. (Pubitemid 39233561)
39. Grunau BE, Wiens MO, Greidanus M. Dantrolene for the treatment of MDMA toxicity. CJEM 2010;12:457-9.
40. Kunitz O, Ince A, Kuhlen R, et al. Hyperpyrexia and rhabdomyolysis after ecstasy (MDMA) intoxication. Anaesthesist 2003;52:511-5. (Pubitemid 36836551)
41. Greene SL, Dargan PI, O'connor N, et al. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 2003;21:121-4. (Pubitemid 36396822)
42. Ferrie R, Loveland RC. Bilateral gluteal compartment syndrome after "ecstasy" hyperpyrexia. J R Soc Med 2000;93:260.
43. Ramcharan S, Meenhorst PL, Otten JM, et al. Survival after massive ecstasy overdose. J Toxicol Clin Toxicol 1998;36:727-31.
44. Williams A, Unwin R. Prolonged elevation of serum creatine kinase (CK) without renal failure after ingestion of ecstasy. Nephrol Dial Transplant 1997;12:361-2. (Pubitemid 27090998)
45. Montgomery H, Myerson S. 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") and associated hypoglycemia. Am J Emerg Med 1997;15:218.
46. Murthy BV, Wilkes RG, Roberts NB. Creatine kinase isoform changes following ecstasy overdose. Anaesth Intensive Care 1997;25:156-9. (Pubitemid 27182729)
47. Coore JR. A fatal trip with ecstasy: a case of 3,4- methylenedioxymethamphetamine/3,4- methylenedioxyamphetamine toxicity. J R Soc Med 1996;89:51P-2P.
48. Ellis AJ, Wendon JA, Portmann B, et al. Acute liver damage and ecstasy ingestion. Gut 1996;38:454-8. (Pubitemid 26074327)
49. Hall AP, Lyburn ID, Spears FD, et al. An unusual ease of ecstasy poisoning. Intensive Care Med 1996;22:670-1.
50. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996;19:157-64. (Pubitemid 26099372)
51. Wake D. Ecstasy overdose: a case study. Intensive Crit Care Nurs 1995;11:6-9.
52. Roberts L, Wright H. Survival following intentional massive overdose of "ecstasy." J Accid Emerg Med 1994;11:53-4.
53. Walsh T, Carmichael R, Chestnut J. A hyperthermic reaction to "ecstasy." Br J Hosp Med 1994;51:476.
54. Nimmo SM, Kennedy BW, Tullett WM, et al. Drug-induced hyperthermia. Anaesthesia 1993;48:892-5.
55. Campkin NT, Davies UM. Another death from ecstacy. J R Soc Med 1992;85:61.
56. Counselman FL. Rhabdomyolysis. In: Tintinalli JE, Kelen GD, Stapczynski JS, editors. Tintinalli's emergency medicine: a comprehensive study guide. 6th ed. Columbus (OH): McGraw-Hill; 2004.
57. Dahl MK, Johansen SS, Ramlau J, et al. Survival after severe ecstasy intoxication. Ugeskr Laeger 2008;170:3678.
58. Archer T. Ecstasy toxicity and the cooling factor. Emerg Med J 2008;25:534.
59. Kunsdorf-Wnuk A, Musiol E, Karpel E, et al. [Rhabdomyolysis, disseminated intravascular coagulation and acute renal failure after severe narcotics intoxication (MDMA, THC, amphetamine)] [article in Polish]. Pol Merkur Lekarski 2005;18:436-9. (Pubitemid 40646347)
60. Karlovsek MZ, Alibegovic A, Balazic J. Our experiences with fatal ecstasy abuse (two case reports). Forensic Sci Int 2005; 147(Suppl):S77-80.
61. Raviña P, Quiroga JM, Raviña T. Hyperkalemia in fatal MDMA ("ecstasy") toxicity. Int J Cardiol 2004;93:307-8. (Pubitemid 38229605)
62. Bordo DJ, Dorfman MA. Ecstasy overdose: rapid cooling leads to successful outcome. Am J Emerg Med 2004;22:326-7. (Pubitemid 38918259)
63. Ben-Abraham R, Szold O, Rudick V, et al. "Ecstasy" intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 2003;10:309-13.
64. Hinkelbein J, Gabel A, Volz M, et al. Suicide attempt with high-dose ecstasy. Anaesthesist 2003;52:51-4.
65. Garcia-Repetto R, Moreno E, Soriano T, et al. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 2003;135:110-4. (Pubitemid 36960216)
66. Finsterer J, Stöllberger C, Steger C, et al. Long lasting impaired cerebral blood flow after ecstasy intoxication. Psychiatry Clin Neurosci 2003;57:221-5. (Pubitemid 36505280)
67. Sue YM, Lee Y, Huang J. Acute hyponatremia, seizure, and rhabdomyolysis after ecstasy use. J Toxicol Clin Toxicol 2002;40:931-2. (Pubitemid 36076749)
68. Nielsen S, Lundemose JB, Simonsen MS, et al. Fatal ecstasy intoxication. Ugeskr Laeger 2001;163:2253-5.
69. Trejo Gutiérrez O, Ortega Romero M, Perea Gainza M, et al. Multiple organ failure associated with use of ecstasy. Rev Clin Esp 2001;201:108-9.
70. Franceschini E, Baronti R, Spaggiari C. Case report: acute poisoning with ecstasy. Minerva Pediatr 2000;52:547-8.
71. Shannon M. Methylenedioxymethamphetamine (MDMA, "ecstasy"). Pediatr Emerg Care 2000;16:377-80.
72. Mueller PD, Korey WS. Death by "ecstasy": The serotonin syndrome? Ann Emerg Med 1998;32:377-380.
73. Drake WM, Broadhurst PA. QT-interval prolongation with ecstasy. S Afr Med J 1996;86:180-1.
74. Lehmann ED, Thom CH, Croft DN. Delayed severe rhabdomyolysis after taking "ecstasy" Postgrad Med J 1995;71:186-7.
75. Satchell SC, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hosp Med 1994;51:495.
76. Barrett PJ, Taylor GT. "Ecstasy" ingestion: a case report of severe complications. J R Soc Med 1993;86:233-4.
77. Fahal IH, Sallomi DF, Yaqoob M, et al. Acute renal failure after ecstasy. BMJ 1992;305:29.
78. Screaton GR, Singer M, Cairns HS, et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 1992;339:677-8.
79. Chadwick IS, Curry PD, Linsley A, et al. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991;84:371.
80. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ("ecstasy"). JAMA 1987; 258:780-1. (Pubitemid 17135891)
81. Simpson DL, Rumack BH. Methylenedioxyamphetamine. clinical description of overdose, death, and review of pharmacology. Arch Intern Med 1981;141:1507-9.
82. Hartung TK, Schofield E, Short AI, et al. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") ingestion. QJM 2002;95:431-7. (Pubitemid 34814661)
83. Brandom BW, Larach MG. The North American malignant hyperthermia registry: reassessment of the safety and efficacy of dantrolene. Anesthesiology 2002;96:A1199.